BofA downgraded Procept BioRobotics (PRCT) to Neutral from Buy with a price target of $38, down from $55.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
- Procept Biorobotics Earnings Call: Growth Amid Challenges
- Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler
- Procept BioRobotics price target lowered to $50 from $85 at TD Cowen
- Procept BioRobotics price target lowered to $51 from $58 at Wells Fargo